- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03476499
Near Infrared Imaging and Flap Necrosis
Near Infrared Imaging for the Assessment of Tissue Viability: Can NIR Images Predict Necrosis?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background of the study:
There are commercial medical devices that measure the spectrum of near infrared light reflected from at a single location of tissue. These non-imaging devices are also called point NIR spectroscopy devices. Point NIR spectroscopy devices have been used to monitor blood perfusion to free flaps and mastectomy flaps. The unit of measurement is StO2; StO2 is a measure of hemoglobin oxygen saturation weighted towards the saturation in the microvascular bed as opposed to SaO2 or SvO2 which correspond to the arterial and venous hemoglobin saturation respectively. StO2 is mixed arterial - venous measure of hemoglobin oxygen saturation. Point devices use a light delivery and collection probe that needs to be in contact with tissue. They can measure on the order of ~10mm deep over an area of approximately 1cm by 1cm depending on the configuration of the device. Some studies using point devices have shown significant differences in StO2 values in flaps that became necrotic versus flaps that remained viable. NIR point systems however are not widely used intraoperatively because they need to be brought in contact with the tissue being measured. They also measure small areas thereby necessitating measurements over many spatially distinct points on the flap to get a comprehensive measurement of flap oxygenation.
Rationale for this study A new commercially available imaging technology uses NIR spectroscopy to measure regional tissue hemoglobin oxygenation, StO2. The device is based on the same principles as point NIR spectroscopy devices but instead of contacting the skin a set of images are taken 12 inches away from the patient. These images are processed to produce a colour coded StO2 image of a large tissue area (~6" by 4"). Since the image device doesn't contact the skin the depth of measurement is ~2mm instead of ~10mm with a point system. Compared to dye based angiography methods, StO2 NIR imaging does not require the injection of a dye. The advantage of the NIR imaging device over point NIR systems is a lack of patient contact. Thus StO2 NIR imaging is completely non-invasive, non-contact. Images can be captured and displayed in less than 5 seconds therefore imaging can be repeated as needed with no risk to the patient and no cost for disposables. Preclinical data shows that NIR can predict necrosis in flaps but clinical data is needed to characterize and assess the value of the technology in plastic and reconstructive surgery.
Study hypotheses or research questions This study will explore the ability of NIR imaging to predict of tissue viability in immediate breast reconstruction procedures. Necrosis will be scored using the SKIN score.
Primary objectives and secondary objectives:
Aim 1: To establish the NIR parameters that are consistent with flap viability. Aim 1: To develop parameters to predict flap viability intraoperatively. Aim 3: To determine if NIR values correspond to SKIN scores
Significance of the study The Innovation is a non-contact, non-invasive means to map/image the oxygen available to an area of tissue. It requires no setup time and there are no consumables associated with its measurement method. As cellular respiration in tissue requires an adequate supply of oxygen, the tissue hemoglobin oxygen saturation image provided by the Innovation can detect areas of tissue that are threatened by a poor oxygen supply. The oxygenation measures provided by the device give surgeons insight into the healing potential of skin flaps in procedures such as mastectomies. Skin flaps that are not sufficiently oxygenated are at risk for necrosis which can be costly to the hospital systems and affect the patient quality of life. The Innovation's oxygenation image assists surgeons in identifying areas of flap ischemia intra-operatively and can be used to monitor flaps post-operatively. With early identification of ischemic areas surgeons can intervene earlier to reduce the risk of flap necrosis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
Toronto, Ontario, Canada, M5G 1X5
- Sinai Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- i. Planned skin flap procedure
- ii. SpO2 above 96%
- iii: Written informed consent.
Exclusion Criteria:
- Use of epinephrine, patent blue V or methelyne blue during procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Planned skin flap procedure
Inclusion Criteria: i. Planned skin flap procedure, ii. SpO2 above 96% and iii: Written informed consent. Exclusion criteria: Use of epinephrine, patent blue V or methelyne blue during procedure. The near infrared imaging NIR device is experimental. Experimental means that the NIR imaging is not used routinely in patients' care. The research will require no extra study visits. Images will be taken at 3 - 4 time points and a separate photo consent will be obtained prior to imaging.
|
Handheld near infrared multispectral imaging device with custom software.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extent of mastectomy skin flap necrosis
Time Frame: 1 month
|
Partial/superficial necrosis and full-thickness necrosis as quantified by a SKIN score.
These areas will be correlated with the intraoperative StO2 values from the NIR images.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infection
Time Frame: 1 month
|
Superficial, deep or organ space surgical site infection.
Patients treated with oral or IV antibiotics will be documented, including patients who have loss of implant due to infection.
|
1 month
|
Wound Dehiscence or Implant Extrusion
Time Frame: 1 month
|
Wound breakdown and/or exposure of implant will be documented.
|
1 month
|
Seroma/Hematoma
Time Frame: 1 month
|
Any evidence of seroma /hematoma will be documented as will any surgical intervention or observation.
|
1 month
|
Removal or Loss of Implant
Time Frame: 1 month
|
Patients who require removal of their implants will be documented along with the reason for removal of implant.
|
1 month
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stefan OP Hofer, PhD, University Health Network, Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAPCR ID:18-5013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flap Necrosis
-
Seoul National University HospitalCompletedBlood Flow | Flap Necrosis | Flap Ischemia | Anastomotic Failure of FlapKorea, Republic of
-
St Vincent's University Hospital, IrelandPelvExCompletedRectal Cancer | Pelvic Cancer | Flap Necrosis | Flap Disorder | Perioperative Complication | Flap IschemiaIreland
-
Aga Khan UniversityCompleted
-
Centre Hospitalier Universitaire, AmiensRecruiting
-
University of British ColumbiaCompleted
-
The Cleveland ClinicCompletedPerfusion; Complications | Skin Flap NecrosisUnited States
-
Hospices Civils de LyonNot yet recruitingFlap Necrosis | Knee Joint Prosthesis Infection | Skin Graft ComplicationsFrance
-
Wake Forest University Health SciencesCompletedPost-Op Complication | Skin Flap NecrosisUnited States
-
Hannover Medical SchoolCompletedFlap MonitoringGermany
-
Xiaofeng BaiUnknownFree Flap ReconstructionChina
Clinical Trials on Near Infrared Imaging (NIR) device
-
University of WashingtonBlaze Bioscience Inc.RecruitingStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); University of TexasCompleted
-
Dana-Farber Cancer InstituteCompleted
-
China Medical University HospitalMinistry of Science and Technology, TaiwanCompletedMajor Depressive Disorder | Oxidative StressTaiwan
-
University Health Network, TorontoSuspendedHead and Neck NeoplasmsCanada
-
Glyconics LtdRecruiting
-
Massachusetts General HospitalBrigham and Women's Hospital; Society of University SurgeonsRecruiting
-
Duke UniversityUnited States Department of DefenseWithdrawn
-
Medical College of WisconsinThe New York Eye & Ear InfirmaryCompletedDiabetic Macular EdemaUnited States
-
Paolo CassanoNorth Suffolk Mental Health Association; Mclean HospitalCompletedMajor Depressive DisorderUnited States